Chengdu Ucello Biotechnology Co., Ltd.

This early-phase study tests a new treatment called CD19/BCMA CAR-T for adults with severe lupus that hasn't improved with standard therapies. About 24 participants will receive a single infusion of these specially engineered immune cells and be closely monitored for safety and d…

This early-phase trial tests whether a patient's own immune cells, modified to target the CLDN18.2 protein, can safely shrink advanced solid tumors. About 18 adults whose cancer has not responded to standard treatments will receive a single infusion of these CAR T-cells. The stud…